Hypertonie bei Menschen mit Diabetes

Zurück zum Zitat Schmidt C et al (2020) Prevalence and incidence of documented diabetes based on health claims data-reference analysis for diabetes surveillance in Germany. Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz 63(1):93–102CrossRefPubMed Schmidt C et al (2020) Prevalence and incidence of documented diabetes based on health claims data-reference analysis for diabetes surveillance in Germany. Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz 63(1):93–102CrossRefPubMed

Zurück zum Zitat Schmidt C et al (2021) Excess mortality in adults with documented diabetes in Germany: routine data analysis of all insurance claims in Germany 2013–2014. BMJ Open 11(1):e41508CrossRefPubMedPubMedCentral Schmidt C et al (2021) Excess mortality in adults with documented diabetes in Germany: routine data analysis of all insurance claims in Germany 2013–2014. BMJ Open 11(1):e41508CrossRefPubMedPubMedCentral

Zurück zum Zitat Wong ND et al (2007) Inadequate control of hypertension in US adults with cardiovascular disease comorbidities in 2003–2004. Arch Intern Med 167(22):2431–2436CrossRefPubMed Wong ND et al (2007) Inadequate control of hypertension in US adults with cardiovascular disease comorbidities in 2003–2004. Arch Intern Med 167(22):2431–2436CrossRefPubMed

Zurück zum Zitat Jia G, Sowers JR (2021) Hypertension in diabetes: an update of basic mechanisms and clinical disease. Hypertension 78(5):1197–1205CrossRefPubMed Jia G, Sowers JR (2021) Hypertension in diabetes: an update of basic mechanisms and clinical disease. Hypertension 78(5):1197–1205CrossRefPubMed

Zurück zum Zitat Stergiou GS et al (2021) 2021 European society of hypertension practice guidelines for office and out-of-office blood pressure measurement. J Hypertens 39(7):1293–1302CrossRefPubMed Stergiou GS et al (2021) 2021 European society of hypertension practice guidelines for office and out-of-office blood pressure measurement. J Hypertens 39(7):1293–1302CrossRefPubMed

Zurück zum Zitat van der Giet M, Scholl U (2022) Secondary hypertension. MMW Fortschr Med 164(Suppl 1):35–41PubMed van der Giet M, Scholl U (2022) Secondary hypertension. MMW Fortschr Med 164(Suppl 1):35–41PubMed

Zurück zum Zitat Brenner BM et al (2001) Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med 345(12):861–869CrossRefPubMed Brenner BM et al (2001) Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med 345(12):861–869CrossRefPubMed

Zurück zum Zitat Mancia G, Kreutz R, Brunström M, Burnier M, Grassi G, Januszewicz A, Muiesan ML, Tsioufis K, Agabiti-Rosei E, Algharably EAE, Azizi M, Benetos A, Borghi C, Hitij JB, Cifkova R, Coca A, Cornelissen V, Cruickshank K, Cunha PG, Danser AHJ, de Pinho RM, Delles C, Dominiczak AF, Dorobantu M, Doumas M, Fernández-Alfonso MS, Halimi JM, Járai Z, Jelaković B, Jordan J, Kuznetsova T, Laurent S, Lovic D, Lurbe E, Mahfoud F, Manolis A, Miglinas M, Narkiewicz K, Niiranen T, Palatini P, Parati G, Pathak A, Persu A, Polonia J, Redon J, Sarafidis P, Schmieder R, Spronck B, Stabouli S, Stergiou G, Taddei S, Thomopoulos C, Tomaszewski M, Van de Borne P, Wanner C, Weber T, Williams B, Zhang ZY, Kjeldsen SE; Authors/Task Force Members (2023) ESH Guidelines for the management of arterial hypertension The Task Force for the management of arterial hypertension of the European Society of Hypertension Endorsed by the European Renal Association (ERA) and the International Society of Hypertension (ISH). J Hypertens. https://doi.org/10.1097/HJH.0000000000003480. Online ahead of print. PMID: 37345492 Mancia G, Kreutz R, Brunström M, Burnier M, Grassi G, Januszewicz A, Muiesan ML, Tsioufis K, Agabiti-Rosei E, Algharably EAE, Azizi M, Benetos A, Borghi C, Hitij JB, Cifkova R, Coca A, Cornelissen V, Cruickshank K, Cunha PG, Danser AHJ, de Pinho RM, Delles C, Dominiczak AF, Dorobantu M, Doumas M, Fernández-Alfonso MS, Halimi JM, Járai Z, Jelaković B, Jordan J, Kuznetsova T, Laurent S, Lovic D, Lurbe E, Mahfoud F, Manolis A, Miglinas M, Narkiewicz K, Niiranen T, Palatini P, Parati G, Pathak A, Persu A, Polonia J, Redon J, Sarafidis P, Schmieder R, Spronck B, Stabouli S, Stergiou G, Taddei S, Thomopoulos C, Tomaszewski M, Van de Borne P, Wanner C, Weber T, Williams B, Zhang ZY, Kjeldsen SE; Authors/Task Force Members (2023) ESH Guidelines for the management of arterial hypertension The Task Force for the management of arterial hypertension of the European Society of Hypertension Endorsed by the European Renal Association (ERA) and the International Society of Hypertension (ISH). J Hypertens. https://​doi.​org/​10.​1097/​HJH.​0000000000003480​. Online ahead of print. PMID: 37345492

Zurück zum Zitat NAVIGATOR Study Group; McMurray JJ, Holman RR, Haffner SM, Bethel MA, Holzhauer B, Hua TA, Belenkov Y, Boolell M, Buse JB, Buckley BM, Chacra AR, Chiang FT, Charbonnel B, Chow CC, Davies MJ, Deedwania P, Diem P, Einhorn D, Fonseca V, Fulcher GR, Gaciong Z, Gaztambide S, Giles T, Horton E, Ilkova H, Jenssen T, Kahn SE, Krum H, Laakso M, Leiter LA, Levitt NS, Mareev V, Martinez F, Masson C, Mazzone T, Meaney E, Nesto R, Pan C, Prager R, Raptis SA, Rutten GE, Sandstroem H, Schaper F, Scheen A, Schmitz O, Sinay I, Soska V, Stender S, Tamás G, Tognoni G, Tuomilehto J, Villamil AS, Vozár J, Califf RM (2010) Effect of valsartan on the incidence of diabetes and cardiovascular events. N Engl J Med 362(16):1477–1490. https://doi.org/10.1056/NEJMoa1001121 NAVIGATOR Study Group; McMurray JJ, Holman RR, Haffner SM, Bethel MA, Holzhauer B, Hua TA, Belenkov Y, Boolell M, Buse JB, Buckley BM, Chacra AR, Chiang FT, Charbonnel B, Chow CC, Davies MJ, Deedwania P, Diem P, Einhorn D, Fonseca V, Fulcher GR, Gaciong Z, Gaztambide S, Giles T, Horton E, Ilkova H, Jenssen T, Kahn SE, Krum H, Laakso M, Leiter LA, Levitt NS, Mareev V, Martinez F, Masson C, Mazzone T, Meaney E, Nesto R, Pan C, Prager R, Raptis SA, Rutten GE, Sandstroem H, Schaper F, Scheen A, Schmitz O, Sinay I, Soska V, Stender S, Tamás G, Tognoni G, Tuomilehto J, Villamil AS, Vozár J, Califf RM (2010) Effect of valsartan on the incidence of diabetes and cardiovascular events. N Engl J Med 362(16):1477–1490. https://​doi.​org/​10.​1056/​NEJMoa1001121

Zurück zum Zitat Group SR et al (2015) A randomized trial of intensive versus standard blood-pressure control. N Engl J Med 373(22):2103–2116CrossRef Group SR et al (2015) A randomized trial of intensive versus standard blood-pressure control. N Engl J Med 373(22):2103–2116CrossRef

Zurück zum Zitat Huang C et al (2017) Systolic blood pressure response in SPRINT (systolic blood pressure intervention trial) and ACCORD (action to control cardiovascular risk in diabetes): a possible explanation for discordant trial results. J Am Heart Assoc. https://doi.org/10.1161/JAHA.117.007509 Huang C et al (2017) Systolic blood pressure response in SPRINT (systolic blood pressure intervention trial) and ACCORD (action to control cardiovascular risk in diabetes): a possible explanation for discordant trial results. J Am Heart Assoc. https://​doi.​org/​10.​1161/​JAHA.​117.​007509

Zurück zum Zitat Bohm M et al (2017) Achieved blood pressure and cardiovascular outcomes in high-risk patients: results from ONTARGET and TRANSCEND trials. Lancet 389(10085):2226–2237CrossRefPubMed Bohm M et al (2017) Achieved blood pressure and cardiovascular outcomes in high-risk patients: results from ONTARGET and TRANSCEND trials. Lancet 389(10085):2226–2237CrossRefPubMed

Zurück zum Zitat Bohm M et al (2021) Renal outcomes and blood pressure patterns in diabetic and nondiabetic individuals at high cardiovascular risk. J Hypertens 39(4):766–774CrossRefPubMed Bohm M et al (2021) Renal outcomes and blood pressure patterns in diabetic and nondiabetic individuals at high cardiovascular risk. J Hypertens 39(4):766–774CrossRefPubMed

Zurück zum Zitat DKIGO (2022) Kidney Disease: Improving Global Outcomes Diabetes Work, G., KDIGO 2022 Clinical Practice Guideline for Diabetes Management in Chronic Kidney Disease. Kidney Int 102(5S):S1–S127 DKIGO (2022) Kidney Disease: Improving Global Outcomes Diabetes Work, G., KDIGO 2022 Clinical Practice Guideline for Diabetes Management in Chronic Kidney Disease. Kidney Int 102(5S):S1–S127

Zurück zum Zitat Scheen AJ (2004) Renin-angiotensin system inhibition prevents type 2 diabetes mellitus. Part 2. Overview of physiological and biochemical mechanisms. Diabetes Metab 30(6):498–505CrossRefPubMed Scheen AJ (2004) Renin-angiotensin system inhibition prevents type 2 diabetes mellitus. Part 2. Overview of physiological and biochemical mechanisms. Diabetes Metab 30(6):498–505CrossRefPubMed

Zurück zum Zitat Bangalore S et al (2016) Diabetes mellitus as a compelling indication for use of renin angiotensin system blockers: systematic review and meta-analysis of randomized trials. BMJ 352:i438CrossRefPubMedPubMedCentral Bangalore S et al (2016) Diabetes mellitus as a compelling indication for use of renin angiotensin system blockers: systematic review and meta-analysis of randomized trials. BMJ 352:i438CrossRefPubMedPubMedCentral

Zurück zum Zitat Yusuf S et al (2008) Telmisartan, ramipril, or both in patients at high risk for vascular events. N Engl J Med 358(15):1547–1559CrossRefPubMed Yusuf S et al (2008) Telmisartan, ramipril, or both in patients at high risk for vascular events. N Engl J Med 358(15):1547–1559CrossRefPubMed

Zurück zum Zitat Dahlof B et al (2005) Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendroflumethiazide as required, in the anglo-scandinavian cardiac outcomes trial-blood pressure lowering arm (ASCOT-BPLA): a multicentre randomised controlled trial. Lancet 366(9489):895–906CrossRefPubMed Dahlof B et al (2005) Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendroflumethiazide as required, in the anglo-scandinavian cardiac outcomes trial-blood pressure lowering arm (ASCOT-BPLA): a multicentre randomised controlled trial. Lancet 366(9489):895–906CrossRefPubMed

Zurück zum Zitat Bangalore S et al (2007) A meta-analysis of 94,492 patients with hypertension treated with beta blockers to determine the risk of new-onset diabetes mellitus. Am J Cardiol 100(8):1254–1262CrossRefPubMed Bangalore S et al (2007) A meta-analysis of 94,492 patients with hypertension treated with beta blockers to determine the risk of new-onset diabetes mellitus. Am J Cardiol 100(8):1254–1262CrossRefPubMed

Zurück zum Zitat Viigimaa M et al (2020) Update of the position paper on arterial hypertension and erectile dysfunction. J Hypertens 38(7):1220–1234CrossRefPubMed Viigimaa M et al (2020) Update of the position paper on arterial hypertension and erectile dysfunction. J Hypertens 38(7):1220–1234CrossRefPubMed

Zurück zum Zitat Chan You S et al (2021) Comprehensive comparative effectiveness and safety of first-line beta-blocker monotherapy in hypertensive patients: a large-scale multicenter observational study. Hypertension 77(5):1528–1538CrossRefPubMed Chan You S et al (2021) Comprehensive comparative effectiveness and safety of first-line beta-blocker monotherapy in hypertensive patients: a large-scale multicenter observational study. Hypertension 77(5):1528–1538CrossRefPubMed

Zurück zum Zitat Tuomilehto J et al (1999) Effects of calcium-channel blockade in older patients with diabetes and systolic hypertension. Systolic hypertension in Europe trial investigators. N Engl J Med 340(9):677–684CrossRefPubMed Tuomilehto J et al (1999) Effects of calcium-channel blockade in older patients with diabetes and systolic hypertension. Systolic hypertension in Europe trial investigators. N Engl J Med 340(9):677–684CrossRefPubMed

Zurück zum Zitat Grossman E, Messerli FH (2004) Are calcium antagonists beneficial in diabetic patients with hypertension? Am J Med 116(1):44–49CrossRefPubMed Grossman E, Messerli FH (2004) Are calcium antagonists beneficial in diabetic patients with hypertension? Am J Med 116(1):44–49CrossRefPubMed

Zurück zum Zitat Jeffers BW et al (2015) A systematic review on the efficacy of Amlodipine in the treatment of patients with hypertension with concomitant diabetes mellitus and/or renal dysfunction, when compared with other classes of antihypertensive medication. Am J Ther 22(5):322–341CrossRefPubMed Jeffers BW et al (2015) A systematic review on the efficacy of Amlodipine in the treatment of patients with hypertension with concomitant diabetes mellitus and/or renal dysfunction, when compared with other classes of antihypertensive medication. Am J Ther 22(5):322–341CrossRefPubMed

Zurück zum Zitat Whelton PK et al (2005) Clinical outcomes in antihypertensive treatment of type 2 diabetes, impaired fasting glucose concentration, and normoglycemia: antihypertensive and lipid-lowering treatment to prevent heart attack trial (ALLHAT). Arch Intern Med 165(12):1401–1409CrossRefPubMed Whelton PK et al (2005) Clinical outcomes in antihypertensive treatment of type 2 diabetes, impaired fasting glucose concentration, and normoglycemia: antihypertensive and lipid-lowering treatment to prevent heart attack trial (ALLHAT). Arch Intern Med 165(12):1401–1409CrossRefPubMed

Zurück zum Zitat Oxlund CS et al (2013) Low dose spironolactone reduces blood pressure in patients with resistant hypertension and type 2 diabetes mellitus. J Hypertens 31(10):2094–2102CrossRefPubMed Oxlund CS et al (2013) Low dose spironolactone reduces blood pressure in patients with resistant hypertension and type 2 diabetes mellitus. J Hypertens 31(10):2094–2102CrossRefPubMed

Zurück zum Zitat Bakris GL et al (2023) A prespecified exploratory analysis from FIDELITY examined finerenone use and kidney outcomes in patients with chronic kidney disease and type 2 diabetes. Kidney Int 103(1):196–206CrossRefPubMed Bakris GL et al (2023) A prespecified exploratory analysis from FIDELITY examined finerenone use and kidney outcomes in patients with chronic kidney disease and type 2 diabetes. Kidney Int 103(1):196–206CrossRefPubMed

Zurück zum Zitat Bakris GL et al (2010) Renal outcomes with different fixed-dose combination therapies in patients with hypertension at high risk for cardiovascular events (ACCOMPLISH): a prespecified secondary analysis of a randomised controlled trial. Lancet 375(9721):1173–1181CrossRefPubMed Bakris GL et al (2010) Renal outcomes with different fixed-dose combination therapies in patients with hypertension at high risk for cardiovascular events (ACCOMPLISH): a prespecified secondary analysis of a randomised controlled trial. Lancet 375(9721):1173–1181CrossRefPubMed

Zurück zum Zitat Williams B et al (2015) Spironolactone versus placebo, bisoprolol, and doxazosin to determine the optimal treatment for drug-resistant hypertension (PATHWAY-2): a randomised, double-blind, crossover trial. Lancet 386(10008):2059–2068CrossRefPubMedPubMedCentral Williams B et al (2015) Spironolactone versus placebo, bisoprolol, and doxazosin to determine the optimal treatment for drug-resistant hypertension (PATHWAY-2): a randomised, double-blind, crossover trial. Lancet 386(10008):2059–2068CrossRefPubMedPubMedCentral

Zurück zum Zitat Nuffield Department of Population Health Renal Studies Group; SGLT2 inhibitor Meta-Analysis Cardio-Renal Trialists’ Consortium (2022) Impact of diabetes on the effects of sodium glucose co-transporter‑2 inhibitors on kidney outcomes: collaborative meta-analysis of large placebo-controlled trials. Lancet 400(10365):1788–1801. https://doi.org/10.1016/S0140-6736(22)02074-8 Nuffield Department of Population Health Renal Studies Group; SGLT2 inhibitor Meta-Analysis Cardio-Renal Trialists’ Consortium (2022) Impact of diabetes on the effects of sodium glucose co-transporter‑2 inhibitors on kidney outcomes: collaborative meta-analysis of large placebo-controlled trials. Lancet 400(10365):1788–1801. https://​doi.​org/​10.​1016/​S0140-6736(22)02074-8